Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment

被引：2

作者：

Tada, Kouki ^{[1
]}

Daizumoto, Kei ^{[1
]}

Takahashi, Masayuki ^{[1
]}

Uehara, Hisanori ^{[2
]}

Tsuda, Megumi ^{[1
]}

Kusuhara, Yoshito ^{[1
]}

Fukawa, Tomoya ^{[1
]}

Yamamoto, Yasuyo ^{[1
]}

Yamaguchi, Kunihisa ^{[1
]}

Kanayama, Hiro-omi ^{[1
]}

机构：

[1] Tokushima Univ, Grad Sch Biomed Sci, Dept Urol, 3-18-15 Kuramoto Cho, Tokushima, Tokushima 7708503, Japan

[2] Tokushima Univ Hosp, Div Pathol, Tokushima, Japan

来源：

IJU CASE REPORTS | 2023年 / 6卷 / 01期

关键词：

molecular-targeted therapy; nivolumab; renal cell carcinoma; sunitinib; MOLECULAR TARGETED THERAPY; CHEMOTHERAPY; INHIBITORS; OUTCOMES; SAFETY;

D O I：

10.1002/iju5.12545

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

IntroductionA case of multiple liver metastases of clear cell RCC with a significant response to sunitinib as the fifth line after nivolumab is reported.Case presentationThe patient was a 65-year-old man who underwent open nephrectomy for RCC. After the nephrectomy, he had recurrences several times, and metastasectomy had been performed for each recurrence. At 13 years after the nephrectomy, multiple liver, and lung metastases appeared. The treatment was switched to axitinib, followed by cabozantinib, then nivolumab. The best response was PR, SD, and PD for these three drugs, and treatment duration was 14, 3, and 3 months, respectively. As the fifth line, sunitinib was administered, with significant shrinkage of the multiple liver metastases, and PR has been maintained for 34 months.ConclusionSunitinib after an IO-drug showed a significant effect in spite of only slight efficacy with other VEGFR-TKIs, which may have occurred through the alteration of the immunological microenvironment.

引用

页码：41 / 44

页数：4

共 14 条

[11] Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study [J].

Soda, Hiroshi ;

Ogawara, Daiki ;

Fukuda, Yuichi ;

Tomono, Hiromi ;

Okuno, Daisuke ;

Koga, Seiko ;

Taniguchi, Hirokazu ;

Yoshida, Masataka ;

Harada, Tatsuhiko ;

Umemura, Asuka ;

Yamaguchi, Hiroyuki ;

Mukae, Hiroshi .

THORACIC CANCER, 2019, 10 (02) :341-346

[12] Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer [J].

Szabados, Bernadett ;

van Dijk, Nick ;

Tang, Yen Zhi ;

van der Heijden, Michiel S. ;

Wimalasingham, Akhila ;

de Liano, Alfonso Gomez ;

Chowdhury, Simon ;

Hughes, Simon ;

Rudman, Sarah ;

Linch, Mark ;

Powles, Thomas .

EUROPEAN UROLOGY, 2018, 73 (02) :149-152

[13] Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy [J].

Templeton, Arnoud J. ;

Knox, Jennifer J. ;

Lin, Xun ;

Simantov, Ronit ;

Xie, Wanling ;

Lawrence, Nicola ;

Broom, Reuben ;

Fay, Andre P. ;

Rini, Brian ;

Donskov, Frede ;

Bjarnason, Georg A. ;

Smoragiewicz, Martin ;

Kollmannsberger, Christian ;

Kanesvaran, Ravindran ;

Alimohamed, Nimira ;

Hermanns, Thomas ;

Wells, J. Connor ;

Amir, Eitan ;

Choueiri, Toni K. ;

Heng, Daniel Y. C. .

EUROPEAN UROLOGY, 2016, 70 (02) :358-364

[14] Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study) [J].

Tomita, Yoshihiko ;

Kimura, Go ;

Fukasawa, Satoshi ;

Numakura, Kazuyuki ;

Sugiyama, Yutaka ;

Yamana, Kazutoshi ;

Naito, Sei ;

Kabu, Koki ;

Tajima, Yohei ;

Oya, Mototsugu .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (06) :966-975

← 1 2 →